News
ChromaDex and the NIH-NIAID Rocky Mountain Laboratories Announce Study to Assess the Therapeutic Potential of Niagen® in COVID-19 Animal Models
Study on ChromaDex's NR ingredient to be conducted at NIH-NIAID's Rocky Mountain Labs, one of the few Biosafety Level 4 labs in the U.S. LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a preclinical study in collaboration with the...
New Preclinical Findings Suggest Boosting NAD+ with Niagen® Holds Potential for Slowing Aging Process and Reducing Metabolic Damage
ChromaDex shares new preclinical and clinical findings revealing potential of Niagen® across a variety of health conditions, paving the way for further clinical research LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced the results of multiple new...
ChromaDex Research & Development Facility Earns ISO/IEC 17025:2017 Accreditation
ChromaDex quality control and R&D facility in Longmont, Colorado obtains ISO/IEC 17025:2017 Accreditation LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced today it has achieved ISO/IEC 17025:2017 quality standard for laboratory testing, the world's most...
ChromaDex to Present at June 2020 Lytham Partners Virtual Investor Growth Conference
LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 2:00pm ET (11:00am PT). A webcast of the...
First-of-Its-Kind Human Tissue Study Finds Link Between NAD Decline and Alcohol-Related Liver Disease (ArLD)
New research from Dr. Charles Brenner expands human conditions with disturbed NAD systems including alcohol-related liver disease (ArLD) and other liver diseases LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC), the global scientific authority on nicotinamide adenine...
ChromaDex to Host Symposium on NAD+ in Human Health and Disease at NUTRITION 2020 LIVE ONLINE Annual Meeting
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced today it has organized a virtual symposium entitled "Nicotinamide Adenine Dinucleotide (NAD+) in Human Health and Disease: The State of the Science on Nutrition Interventions" tomorrow Tuesday, June 2, from 8:30 to...
ChromaDex to Participate in Panel on Master Files for Dietary Supplements Hosted by the American Conference Institute (ACI) and Council for Responsible Nutrition (CRN)
ChromaDex joins industry leaders to discuss "What New Dietary Ingredient Master Files Mean for Innovation & Compliance" LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced its participation in a panel discussion titled "What New Dietary Ingredient Master...
ChromaDex Chief Scientific Advisor Dr. Charles Brenner Receives 2020 National Scientific Achievement Award from the American Society for Nutrition
Dr. Charles Brenner's latest research focuses on effect of SARS-CoV-2 infection on cells' NAD levels LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa and...
ChromaDex Corporation Reports First Quarter 2020 Financial Results
First Quarter 2020 Highlights vs. First Quarter 2019 Strong growth in net sales to $14.3 million, higher gross margins, and significantly improved marketing efficiency year-over-year. Tru Niagen net sales of $11.1 million, a 50% increase year-over-year. Net loss was...
Ninth Published Human Trial on Niagen® Nicotinamide Riboside (NR) Shows Increase in NAD+ Levels, Additional Research Highlights Downfalls of Nicotinamide Mononucleotide (NMN)
ChromaDex highlights additional clinical and preclinical research strengthening science and understanding behind Niagen® (patented nicotinamide riboside) LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced the results of several new studies, which have...